Induced pluripotent stem cells (iPSCs) derived from af pre-symptomatic carrier of a R406W mutation in microtubule-associated protein tau (MAPT) causing frontotemporal dementia by Rasmussen, Mikkel A. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Induced pluripotent stem cells (iPSCs) derived from af pre-symptomatic carrier of a
R406W mutation in microtubule-associated protein tau (MAPT) causing frontotemporal
dementia
Rasmussen, Mikkel A.; Hjermind, Lena Elisabeth; Hasholt, Lis Frydenreich; Waldemar,
Gunhild; Nielsen, Jørgen Erik; Clausen, Christian; Hyttel, Poul; Holst, Bjørn
Published in:
Stem Cell Research
DOI:
10.1016/j.scr.2015.12.012
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Rasmussen, M. A., Hjermind, L. E., Hasholt, L. F., Waldemar, G., Nielsen, J. E., Clausen, C., ... Holst, B. (2016).
Induced pluripotent stem cells (iPSCs) derived from af pre-symptomatic carrier of a R406W mutation in
microtubule-associated protein tau (MAPT) causing frontotemporal dementia. Stem Cell Research, 16(1), 105-
109. https://doi.org/10.1016/j.scr.2015.12.012
Download date: 09. okt.. 2020
Stem Cell Research 16 (2016) 105–109
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab resource: Stem cell lineInduced pluripotent stem cells (iPSCs) derived from a pre-symptomatic
carrier of a R406W mutation in microtubule-associated protein tau
(MAPT) causing frontotemporal dementiaMikkel A. Rasmussen a,⁎, Lena E. Hjermind b, Lis F. Hasholt c, Gunhild Waldemar b, Jørgen E. Nielsen b,
Christian Clausen a, Poul Hyttel d, Bjørn Holst a
a Bioneer A/S, Kogle Alle 2, 2970 Hoersholm, Denmark
b Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
c Institute of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 N, Denmark
d Department of Veterinary Clinical and Animal Sciences, Section for Anatomy & Biochemistry, University of Copenhagen, Groennegårdsvej 7, 1870 Frb C, DenmarkIn
P
C
D
O
Ty
Su
K
A
⁎ Corresponding author.
http://dx.doi.org/10.1016/j.scr.2015.12.012
1873-5061/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 20 November 2015
Received in revised form 9 December 2015
Accepted 18 December 2015
Available online 23 December 2015Skin fibroblasts were obtained from a 28-year-old pre-symptomatic woman carrying a R406W mutation in
microtubule-associated protein tau (MAPT), known to cause frontotemporal dementia. Induced pluripotent
stem cell (iPSCs) were established by electroporation with episomal plasmids containing hOCT4, hSOX2, hKLF2,
hL-MYC, hLIN-28 and shP53. iPSCs were free of genomically integrated reprogramming genes, contained the ex-
pected c.1216CNT substitution in exon 13 of the MAPT gene, expressed the expected pluripotency markers,
displayed in vitro differentiation potential to the three germ layers and had normal karyotype. The iPSC line
may be useful for studying hereditary frontotemporal dementia and TAU pathology in vitro.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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gous for a R406W mutation in microtubule-associated protein tau
(MAPT), which can cause frontotemporal dementia. However, the
woman was pre-symptomatic at the time of biopsy (Lindquist
et al., 2008). Reprogramming was performed by electroporation
with three episomal plasmids containing hOCT4 with or without a
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establish integration-free iPSC from an 18-year old healthy male
(Rasmussen et al., 2014). Four weeks after reprogramming, an aver-
age of 32 colonies per 1 × 105 fibroblasts (0.03%) emerged with the
inclusion of shp53, whereas, no colonies were observed without
shp53. Integration analysis with plasmid-specific primers showed
that hOCT4, hSOX2 and hLIN28, present on each of the three plasmids,
had not integrated into the genome (Fig 1A) and sequencing con-
firmed the presence of a c.1216CNT substitution in one of the alleles
of exon 13 in the MAPT gene corresponding to a R406W mutation
(Fig 1B). Pluripotency analysis showed that transcription from the
endogenous pluripotency genes NANOG, POU5F1 (OCT4), TDGF1,
DNMT3B, GABRB3 and GDF3 were between 100 and 10,000 times
upregulated compared with fibroblasts (Fig 1C) and immunocyto-
chemical (ICC) analysis demonstrated the presence of the
pluripotency markers OCT4, NANOG, TRA1-60, TRA1-81, SSEA3 and
SSEA4 at the protein level (Fig 1D). Finally, in vitro differentiation
followed by ICC analysis with the mesodermal marker smooth mus-
cle actin (SMA), the endodermal marker alpha-feto protein (AFP)Fig. 1. A. Integration analysis. Quantitative PCR (qPCR) on genomic DNA from H236 C6 induc
episomal plasmids (positive control) with plasmid-specific primers of hOCT4, hSOX2, and hLIN
B. Sequencing of mutation. Sequencing of exon 13 of theMAPT gene in H236 C6 induced plur
red arrow. C. Pluripotency expression analysis. Quantitative reverse-transcriptase PCR (qRT-
fibroblasts and the iPSC line BIONi010-A (Rasmussen et al., 2014) as a positive control with th
GDF3. Relative expression is shown as the fold change (2-ΔΔCt) with GAPDH and fibroblasts
C6 induced pluripotent stem cells with the pluripotency markers OCT3/4, TRA1-81, NANOG,
Immunocytochemical staining of plated embryoid bodies (EBs) from H236 C6 induced pluripo
betaIII-tubulin (TUJI). Scale bars correspond to 100 μm. F. Karyotyping. Representative karyotyand the ectodermal marker beta-III-tubulin (TUJI) demonstrated
the differentiation potential into all three germ layers (Fig 1E).
2. Materials and methods
Unless otherwise stated, consumables and reagents were purchased
from Sigma-Aldrich, St. Louis, MO, USA.
2.1. Establishment of iPSC
A skin biopsy was obtained from a 28-year old woman carrying a
R406Wmutation in MAPT. The study was approved by the regional sci-
entific ethical committee in the Capital Region of Denmark (RH), and
written informed consent was obtained from the donor. Fibroblasts
were cultured in fibroblast medium, consisting of Dulbecco's Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and 1% penicillin and streptomycin (Pen/
Strep). 1 × 105 fibroblasts were electroporated with a total of 1 μg of
episomal plasmids containing hOCT4 with or without a short hairpined pluripotent stem cells (iPSC), fibroblasts and a pool of fibroblasts electroporated with
28. Data is shown as the fold change (2−ΔΔCt) with GAPDH and fibroblasts as references.
ipotent stem cells showing a c.1216CNT substitution in one of the alleles marked with a
PCR) expression analyses on cDNA from H236 C6 induced pluripotent stem cells (iPSC),
e endogenous pluripotency genes NANOG, POU5F1 (OCT4), TDGF1, DNMT3B, GABRB3 and
as references. D. Immunofluorescence staining. Immunocytochemical detection of H236
TRA1-60, SSEA3, and SSEA4. Scale bars correspond to 400 μm. E. In vitro differentiation.
tent stem cells on day 28 with smooth muscle actin (SMA), alpha-fetoprotein (AFP) and
pe of H236 C6 induced pluripotent stem cells.
Fig. 1 (continued).
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hSOX2 and hKLF4 (Addgene plasmid 27078), and hL-MYC and hLIN28
(Addgene plasmid 27080; Okita et al., 2011) and cultured in fibroblast
medium. Electroporation was carried out using a Neon™ electropora-
tion device with two pulses at 1200 V for 20 ms (Life Technologies,
Carlsbad, CA, USA). One week after electroporation, the fibroblasts
were trypsinized and split 1:2 onto hESC-qualified Matrigel-coated
dishes (BD Biosciences, Franklin Lakes, NJ, USA) and cultured in
mTeSR1 medium (Stem Cell Technologies, Vancouver, BC, Canada) in
5% O2, 5% CO2 in N2. After four weeks, primary iPSC colonies were dis-
sected out manually, transferred to new Matrigel-coated dishes, and
cultured in mTeSR1. The iPSC lines were split 1:6 every 5–6 days with
Dispase (Stem Cell Technologies, Vancouver, BC, Canada). At passage
10, the iPSC lines were harvested for subsequent analyses or frozen in
liquid nitrogen in mTeSR1 containing 10% DMSO.
2.2. Integration analysis
DNA was purified from iPSCs, fibroblasts and a pool of fibroblasts
electroporated with episomal plasmids as a positive control using theDNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). qPCR analysis
was carried out with the primers OCT4-pla, SOX2-pla and LIN-28-pla,
which are specific to the three plasmids (Okita et al., 2011) and data
was analyzed using the 2−ΔΔCt method relative to GAPDH with fibro-
blasts as a reference (set to 1).2.3. Pluripotency expression analysis
Total RNA was purified from iPSCs, fibroblasts and the iPSC line
BIONi010-A (Rasmussen et al., 2014) as a positive control using RNeasy
mini kit (Qiagen, Hilden, Germany). Conversion to cDNAwas performed
with RevertAid First Strand cDNA synthesis kit (Thermo Scientific,
Waltham, MA, USA). qPCR analysis was carried out using the TaqMan
primers GAPDH Hs03929097_g1, NANOG Hs02387400_g1, POU5F1
Hs00999632_g1, TDGF1 Hs02339497_g1, DMNT3B Hs00171876_m1,
GABRB3 Hs00241459_m1 and GDF3 Hs00220998_m1 (Thermo Scientific,
Waltham, MA, USA; International Stem Cell Banking Initiative). Data
was analyzed using the 2−ΔΔCt method relative to GAPDH with fibro-
blasts as a reference (set to 1).
Fig. 1 (continued).
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Sanger sequencing of exon 13 of the MAPT gene was carried out in
an ABI PRISM 310 Genetic Analyzer using the primers MAPT_Ex13Fw
ctggtctttctctggcactt and MAPT_Ex13Rv accaattaaccgaactgcg
(NM_001123066.3; Lindquist et al., 2008).2.5. Immunofluorescence staining
iPSCs were fixed with 4% paraformaldehyde (PFA) in PBS for 15min
and stained by standard immunofluorescence procedures. The primary
antibodies (Table 1) were visualized with the secondary antibodies
Alexa 488 or Alexa 594 diluted 1:400 (Life technologies, Carlsbad, CA,
USA) and counterstained with Hoechst bisbenzimide 33258. ImagesTable 1
Antibodies used for immunocytochemistry.
Antibody and host species
Pluripotency Rabbit anti-NANOG
Goat anti-OCT4
Rat anti-SSEA3
Mouse anti-SSEA4
Mouse anti-Tra-1-81
Mouse anti-Tra-1-60
In vitro differentiation Mouse anti-smooth muscle actin (SMA)
Rabbit anti-alpha-1-fetoprotein (AFP)
Mouse anti-Beta-III-tubulin (TUJI)were acquired on a Leica DMRB-fluorescence microscope (Leica
Microsystems, Wetzlar, Germany).2.6. In vitro differentiation
Embryoid body (EB) formation was performed by transferring
Dispase-treated clumps of iPSC to ultra-low attachment plates (Corning,
Corning, NY, USA) in mTeSR1. After 2 days of culture, the medium was
changed to DMEM/F12 containing 20% knockout serum replacement
(Life Technologies, Carlsbad, CA, USA), 1× non-essential amino acid,
2 mM L-glutamine, 0.1 mM 2-mercaptoethanol and 1% pen/strep.
After 7 days, the EBs were plated on 0.1% gelatin-coated culture dishes
and cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine
and 1% pen/strep for up to three weeks. The cells were fixed for 15 minDilution Company and catalog number
1:500 Peprotech, 500-P236
1:500 Santa Cruz, sc-8628
1:100 Biolegend, 330302
1:100 Biolegend, 330402
1:200 Biolegend, 330702
1:200 Biolegend, 330602
1:500
1:500
DAKO, M0851
DAKO, A0008
1:4000 Sigma-Aldrich, T8660
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(Table 1).2.7. Karyotyping
iPSCs and fibroblasts were treated for 45 min with KaryoMAX
Colcemid (Life Technologies, Carlsbad, CA, USA) and harvested in fresh
fixative containing 25% acetic acid and 75% methanol. Karyotyping
was performed on G-banded metaphase chromosomes using standard
cytogenetic procedures.3. Verification and authentication
Karyotyping was performed at the Center for Applied Human
Molecular Genetics, Kennedy Center, Glostrup, Denmark. At least
10 metaphases were analyzed per sample with an approximate res-
olution of 550 to 600 bands per haploid genome. The results showed
a normal 46, XX karyotype, free of any discernible abnormalities
(Fig. 1F). iPSC line identity and purity was confirmed by sequencing
of the MAPT gene (Fig. B) and ICC with pluripotency markers
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